Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clindamycin/tretinoin - Stiefel Laboratories

Drug Profile

Clindamycin/tretinoin - Stiefel Laboratories

Alternative Names: Clindamycin phosphate/tretinoin gel; CT Gel; Velac; Veltin

Latest Information Update: 05 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma BV
  • Developer Stiefel Laboratories
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris
  • Registered Acne

Most Recent Events

  • 05 Jul 2019 Chemical structure information added
  • 23 Nov 2015 Clindamycin/tretinoin 1.2%/0.025% gel licensed to Almirall in USA
  • 13 Aug 2013 No development reported - Phase-III for Acne vulgaris (in adolescents, in adults) in USA, Belize and Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top